UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created position of VP, Clinical Science, based in the USA. 7 May 2014
US-based pharmacogenetics company Millennium Laboratories has announced the appointment of Nikhil Nayak as chief marketing officer, Steven Soe as chief compliance officer, and Michael Flowers as vice president, government operations. 6 May 2014
Japanese drug major Astellas Pharma has announced the promotions of Bernhardt Zeiher to executive vice president, Global Development and Jeannette Barrett to vice president and head of Medical Excellence, Global Medical Affairs. 6 May 2014
UK-based cancer therapeutics firm Scancell has announced the appointment of Sally Adams to the board as Development Director with immediate effect. 1 May 2014
UK nanotechnology firm Midatech has announced the appointments of Rolf Stahel as chairman and Craig Cook as Chief Operating Officer (COO) and Chief Medical Officer (CMO). 1 May 2014
US biopharmaceutical company Coherus Biosciences has announced the appointment of Michael Fleming as senior vice president, commercial strategy. 28 April 2014
UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. 28 April 2014
Novartis Vaccines, the vaccination branch of Swiss drug major Novartis (NOVN: VX), has announced the appointment of Dr John Porter to the position of Medical Affairs Director for Cluster North Europe. 25 April 2014
Digital medicines company Proteus Health, have announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. 25 April 2014
China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer. 24 April 2014
US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson as President and Chief Executive Officer effective April 29, 2014. 24 April 2014
Japanese drugmaker Daiichi Sankyo has announced that Ken Keller will join the company as President of its Commercial operations in the United States. 23 April 2014
Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and Richard Francis as new Division Head of Sandoz. 22 April 2014
South African drugmaker Adcock Ingram has announced the appointment of Kevin Wakeford (pictured) as Chief Executive Officer, with immediate effect. 22 April 2014
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024